M. Zoni-berisso, F. Lercari, T. Carazza, and S. Domenicucci, Epidemiology of atrial fibrillation: European perspective, Clinical Epidemiology, vol.6, pp.213-233, 2014.
DOI : 10.2147/CLEP.S47385

R. Hart, L. Pearce, and M. Aguilar, Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation, Annals of Internal Medicine, vol.146, issue.12, pp.857-67, 2007.
DOI : 10.7326/0003-4819-146-12-200706190-00007

S. Connolly, J. Eikelboom, and C. Joyner, Apixaban in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.364, issue.9
DOI : 10.1056/NEJMoa1007432

S. Connolly, M. Ezekowitz, and S. Yusuf, Dabigatran versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.361, issue.12, pp.1139-51, 2009.
DOI : 10.1056/NEJMoa0905561

R. Giugliano, C. Ruff, and E. Braunwald, Edoxaban versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.369, issue.22, pp.2093-104, 2013.
DOI : 10.1056/NEJMoa1310907
URL : https://hal.archives-ouvertes.fr/hal-00934699

M. Patel, K. Mahaffey, and J. Garg, Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.10, pp.883-91, 2011.
DOI : 10.1056/NEJMoa1009638
URL : https://hal.archives-ouvertes.fr/hal-01038111

A. Camm, G. Lip, D. Caterina, and R. , 2012 Focused Update of the ESC Guidelines for the Management of Atrial Fibrillation, Revista Espa??ola de Cardiolog??a (English Edition), vol.66, issue.1, pp.1385-413, 2012.
DOI : 10.1016/j.rec.2012.11.003

C. January, L. Wann, and J. Alpert, 2014 AHA/ACC/HRS Guideline for??the??Management of Patients With??Atrial Fibrillation, Journal of the American College of Cardiology, vol.64, issue.21, pp.1-76, 2014.
DOI : 10.1016/j.jacc.2014.03.022

G. Lip, C. Laroche, and G. Dan, A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry, Europace, vol.16, issue.3, pp.308-327, 2014.
DOI : 10.1093/europace/eut373

R. Martins, K. Kaur, and E. Hwang, Dominant frequency increase rate predicts transition from paroxysmal to long-term persistent atrial fibrillation New oral anticoagulants in patients with atrial fibrillation -Authors'reply, Circulation Lancet, vol.129384, issue.12, pp.1472-8225, 2014.

M. Molteni, P. Friz, H. Primitz, L. Marano, G. Boracchi et al., The definition of valvular and non-valvular atrial fibrillation: results of a physicians' survey, Europace, vol.16, issue.12
DOI : 10.1093/europace/euu178

J. Blackshear and J. Odell, Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation, The Annals of Thoracic Surgery, vol.61, issue.2, pp.755-764, 1996.
DOI : 10.1016/0003-4975(95)00887-X

N. Fukuda, T. Hirai, K. Ohara, K. Nakagawa, T. Nozawa et al., Relation of the severity of mitral regurgitation to thromboembolic risk in patients with atrial fibrillation, International Journal of Cardiology, vol.146, issue.2, pp.197-201, 2011.
DOI : 10.1016/j.ijcard.2009.06.051

H. Nakagami, K. Yamamoto, U. Ikeda, T. Mitsuhashi, T. Goto et al., Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation, American Heart Journal, vol.136, issue.3, pp.528-560, 1998.
DOI : 10.1016/S0002-8703(98)70231-5

G. Breithardt, H. Baumgartner, and S. Berkowitz, Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial, European Heart Journal, vol.35, issue.47, pp.3377-85, 2014.
DOI : 10.1093/eurheartj/ehu305

A. Avezum, R. Lopes, and P. Schulte, Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseCLINICAL PERSPECTIVE, Circulation, vol.132, issue.8, pp.624-656, 2015.
DOI : 10.1161/CIRCULATIONAHA.114.014807

S. Cannegieter, F. Rosendaal, and E. Briet, Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses, Circulation, vol.89, issue.2, pp.635-676, 1994.
DOI : 10.1161/01.CIR.89.2.635

E. Briet, Optimal oral anticoagulant therapy in patients with mechanical heart valves, N Engl J Med, vol.333, pp.11-18, 1995.

J. Eikelboom, M. Brueckmann, and F. Van-de-werf, Dabigatran in patients with mechanical heart valves, N Engl J Med, vol.370, pp.383-387, 2014.

R. Bonow, B. Carabello, and K. Chatterjee, Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular, 2008.

. Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons, Circulation, vol.118, pp.523-661, 2008.

R. Nishimura, C. Otto, and R. Bonow, ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Guidelines on the management of valvular heart disease, pp.521-6432451, 2012.

R. Whitlock, J. Sun, S. Fremes, F. Rubens, and K. Teoh, Antithrombotic and Thrombolytic Therapy for Valvular Disease, Chest, vol.141, issue.2, pp.576-600, 2012.
DOI : 10.1378/chest.11-2305
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278057

R. Philippart, A. Brunet-bernard, and N. Clementy, Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project, Thromb Haemost, vol.115132132, issue.29, pp.1056-63, 2016.

S. Mckellar, S. Abel, C. Camp, R. Suri, M. Ereth et al., Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves, The Journal of Thoracic and Cardiovascular Surgery, vol.141, issue.6, pp.1410-1416, 2011.
DOI : 10.1016/j.jtcvs.2011.02.011

J. Schomburg, E. Medina, M. Lahti, and R. Bianco, Dabigatran versus Warfarin after Mechanical Mitral Valve Replacement in the Swine Model, Journal of Investigative Surgery, vol.28, issue.3, pp.150-155, 2012.
DOI : 10.1532/HSF98.20041015

I. Jaffer, A. Stafford, J. Fredenburgh, R. Whitlock, N. Chan et al., Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation Comparison of unfractionated heparin, lowmolecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study, J Am Heart Assoc J Thromb Thrombolysis, vol.432, pp.417-442, 2011.

L. Greiten, S. Mckellar, J. Rysavy, and H. Schaff, Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model, European Journal of Cardio-Thoracic Surgery, vol.45, issue.5, pp.914-923, 2014.
DOI : 10.1093/ejcts/ezt545

S. Connolly, J. Pogue, and J. Eikelboom, Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range, Circulation, vol.118, issue.20, pp.2029-2066, 2008.
DOI : 10.1161/CIRCULATIONAHA.107.750000

D. Caterina, R. , J. Camm, and A. , Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial, Europace, vol.18, issue.1, pp.6-11, 2016.
DOI : 10.1093/europace/euv288

D. Caterina, R. Camm, and A. , What is ???valvular??? atrial fibrillation? A reappraisal, European Heart Journal, vol.35, issue.47, pp.3328-3363, 2014.
DOI : 10.1093/eurheartj/ehu352